Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

Incyte Corporation INCY reported second-quarter 2025 adjusted earnings of $1.57 per share, which beat the Zacks Consensus ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Eli Lilly has been gaining ground on Novo Nordisk in this sector, intensifying the pressure on the company to innovate and regain market share. The leadership change comes at a crucial time as Novo ...

Investing.com -- Novo Nordisk (NYSE: NVO )’s guidance reduction and CEO resignation represent a "double surprise" according to BMO Capital Markets analyst Evan David Seigerman. In a note to clients, ...